Literature DB >> 30197875

Multifactorial regulators of tumor programmed death-ligand 1 (PD-L1) response.

R Dixon Dorand1, Agne Petrosiute1,2,3, Alex Y Huang1,2,3.   

Abstract

Entities:  

Year:  2017        PMID： 30197875      PMCID： PMC6124672          DOI： 10.21037/tcr.2017.11.08

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  26 in total

1.  Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.

Authors:  Asaka Kondo; Taishi Yamashita; Hideto Tamura; Wanhong Zhao; Takashi Tsuji; Masumi Shimizu; Eiji Shinya; Hidemi Takahashi; Koji Tamada; Lieping Chen; Kazuo Dan; Kiyoyuki Ogata
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

2.  Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274).

Authors:  Seung-Jin Lee; Byeong-Churl Jang; Soo-Woong Lee; Young-Il Yang; Seong-Il Suh; Yeong-Min Park; Sangtaek Oh; Jae-Gook Shin; Sheng Yao; Lieping Chen; In-Hak Choi
Journal:  FEBS Lett       Date:  2006-01-09       Impact factor: 4.124

3.  Deubiquitination and Stabilization of PD-L1 by CSN5.

Authors:  Seung-Oe Lim; Chia-Wei Li; Weiya Xia; Jong-Ho Cha; Li-Chuan Chan; Yun Wu; Shih-Shin Chang; Wan-Chi Lin; Jung-Mao Hsu; Yi-Hsin Hsu; Taewan Kim; Wei-Chao Chang; Jennifer L Hsu; Hirohito Yamaguchi; Qingqing Ding; Yan Wang; Yi Yang; Chung-Hsuan Chen; Aysegul A Sahin; Dihua Yu; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Cancer Cell       Date:  2016-11-17       Impact factor: 31.743

Review 4.  Immune Checkpoint Blockade in Cancer Therapy.

Authors:  Michael A Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

5.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

Review 6.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

7.  CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.

Authors:  Marian L Burr; Christina E Sparbier; Yih-Chih Chan; James C Williamson; Katherine Woods; Paul A Beavis; Enid Y N Lam; Melissa A Henderson; Charles C Bell; Sabine Stolzenburg; Omer Gilan; Stuart Bloor; Tahereh Noori; David W Morgens; Michael C Bassik; Paul J Neeson; Andreas Behren; Phillip K Darcy; Sarah-Jane Dawson; Ilia Voskoboinik; Joseph A Trapani; Jonathan Cebon; Paul J Lehner; Mark A Dawson
Journal:  Nature       Date:  2017-08-16       Impact factor: 49.962

Review 8.  Cancer immunotherapies targeting the PD-1 signaling pathway.

Authors:  Yoshiko Iwai; Junzo Hamanishi; Kenji Chamoto; Tasuku Honjo
Journal:  J Biomed Sci       Date:  2017-04-04       Impact factor: 8.410

9.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

10.  PDL1 Regulation by p53 via miR-34.

Authors:  Maria Angelica Cortez; Cristina Ivan; David Valdecanas; Xiaohong Wang; Heidi J Peltier; Yuping Ye; Luiz Araujo; David P Carbone; Konstantin Shilo; Dipak K Giri; Kevin Kelnar; Desiree Martin; Ritsuko Komaki; Daniel R Gomez; Sunil Krishnan; George A Calin; Andreas G Bader; James W Welsh
Journal:  J Natl Cancer Inst       Date:  2015-11-17       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.